Abstract
Ecthyma is an ulcerative pyoderma of the skin, well known to be caused by S aureus and/or group A Streptococcus. Bevacizumab is an IgG1 humanized monoclonal antibody that neutralizes the effect of vascular endothelial growth factor (VEGF), which is for use in the treatment of multiple cancer. However, in bevacizumab, by inhibiting the pathway of VEGF that can interfere wound repair, and several cases have been reported of delayed wound healing in postoperative patients with bevacizumab. In our case, it is highly possible that bevacizumab disrupted wound healing process, and that ecthyma was caused by a secondary infection at the injection site.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
